A 28-year-old man from Delhi presents with dysuria and purulent urethral discharge for 3 days. He reports unprotected sexual contact with a new partner 5 days ago. On examination, the urethral meatus is inflamed and a thick, greenish-yellow discharge is expressed. Gram stain of the urethral smear shows gram-negative diplococci within polymorphonuclear leukocytes. What is the most appropriate next step in management?

Explanation

## Diagnosis and Clinical Presentation **Key Point:** The clinical triad of dysuria, purulent urethral discharge, and gram-negative intracellular diplococci on Gram stain is pathognomonic for *Neisseria gonorrhoeae* (gonococcal urethritis). ## Organism Identification The Gram stain finding of gram-negative diplococci within polymorphonuclear leukocytes (PMNs) is diagnostic: - Kidney bean or coffee bean morphology - Intracellular location within neutrophils - Thick, purulent discharge (unlike chlamydial discharge which is mucopurulent) ## Treatment Guidelines **High-Yield:** Current WHO and CDC guidelines (2023) recommend: | Parameter | Ceftriaxone | Cefixime | Doxycycline | Azithromycin | |-----------|-------------|----------|-------------|---------------| | **Dose** | 250 mg IM single | 400 mg oral single | 100 mg BD × 7 days | 1 g oral single | | **Efficacy** | >99% | ~95% | Not recommended | Resistance emerging | | **Resistance** | Minimal | Increasing | High resistance | High resistance | | **First-line** | Yes | Alternative | No | No | **Clinical Pearl:** Ceftriaxone 250 mg IM is the gold standard for uncomplicated gonococcal urethritis because: 1. Highest cure rates (>99%) 2. Minimal resistance globally 3. Single-dose compliance 4. Effective in pharyngeal and rectal infections ## Why Ceftriaxone Over Alternatives **Mnemonic: CAD** — **C**eftriaxone is the **A**ntibacterial **D**rug of choice - **Doxycycline:** Resistance in *N. gonorrhoeae* now exceeds 50% in many regions; no longer recommended as monotherapy - **Cefixime:** Oral bioavailability is variable; resistance rates increasing; reserved only when IM administration impossible - **Azithromycin:** Widespread resistance (>30%); no longer recommended by WHO/CDC ## Concurrent Chlamydial Coverage **Warning:** Although this patient has gonococcal urethritis (Gram stain positive), co-infection with *Chlamydia trachomatis* occurs in 20–40% of cases. Current guidelines recommend concurrent azithromycin 1 g single dose OR doxycycline 100 mg BD × 7 days AFTER ceftriaxone, though the question asks for the most appropriate NEXT step, which is ceftriaxone monotherapy for gonorrhea. [cite:Harrison 21e Ch 163]